A role for β-dystroglycan in the organization and structure of the nucleus in myoblasts  by Martínez-Vieyra, Ivette A. et al.
Biochimica et Biophysica Acta 1833 (2013) 698–711
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrA role for β-dystroglycan in the organization and structure of the nucleus
in myoblasts
Ivette A. Martínez-Vieyra a, Alejandra Vásquez-Limeta a, Ricardo González-Ramírez b,
Sara L. Morales-Lázaro c, Mónica Mondragón d, Ricardo Mondragón d, Arturo Ortega a,
Steve J. Winder e, Bulmaro Cisneros a,⁎
a Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV-IPN), México, D.F. 07360, Mexico
b Departamento de Biología Molecular e Histocompatibilidad, Hospital General Dr. Manuel Gea González, Mexico, D.F., Mexico
c División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México, D.F., Mexico
d Departamento de Bioquímica, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV-IPN), México, D.F. 07360, Mexico
e Department of Biomedical Science, University of Shefﬁeld, Shefﬁeld, UKAbbreviations: NE, Nuclear envelope; INM, Inner nu
nuclear membrane
⁎ Corresponding author at: Departamento de Genétic
de Investigación y de Estudios Avanzados del IPN, Av.
2508, Col. San Pedro Zacatenco, Delegación Gustavo A
Postal 07360, Apartado Postal: 14-740, 07000, Mexico.
fax: +52 55 5747 3800x5355.
E-mail address: bcisnero@cinvestav.mx (B. Cisneros
0167-4889/$ – see front matter © 2012 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbamcr.2012.11.019a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 July 2012
Received in revised form 17 November 2012
Accepted 24 November 2012
Available online 4 December 2012
Keywords:
Dystroglycan
Emerin
Nuclear lamins
Nuclear envelope
NucleoliWe recently characterized a nuclear import pathway for β-dystroglycan; however, its nuclear role remains un-
known. In this study, we demonstrate for the ﬁrst time, the interaction of β-dystroglycan with distinct proteins
from different nuclear compartments, including the nuclear envelope (NE) (emerin and lamins A/C and B1),
splicing speckles (SC35), Cajal bodies (p80-coilin), and nucleoli (Nopp140). Electron microscopy analysis re-
vealed that β-dystroglycan localized in the inner nuclear membrane, nucleoplasm, and nucleoli. Interestingly,
downregulation of β-dystroglycan resulted in both mislocalization and decreased expression of emerin and
lamin B1, but not lamin A/C, as well in disorganization of nucleoli, Cajal bodies, and splicing speckles with the
concomitant decrease in the levels of Nopp140, and p80-coilin, but not SC35. Quantitative reverse transcription
PCR and cycloheximide-mediated protein arrest assays revealed that β-dystroglycan deﬁciency did not change
mRNA expression of NE proteins emerin and lamin B1 bud did alter their stability, accelerating protein turnover.
Furthermore, knockdown of β-dystroglycan disrupted NE-mediated processes including nuclear morphology
and centrosome-nucleus linkage, which provides evidence that β-dystroglycan association with NE proteins is
biologically relevant. Unexpectedly, β-dystroglycan-depleted cells exhibited multiple centrosomes, a character-
istic of cancerous cells. Overall, these ﬁndings imply that β-dystroglycan is a nuclear scaffolding protein involved
in nuclear organization and NE structure and function, and that might be a contributor to the biogenesis of nu-
clear envelopathies.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Eukaryotic cell function depends on the physical separation of nu-
cleoplasmic and cytoplasmic components by the nuclear envelope
(NE). The NE is composed of the outer nuclear membrane (ONM),
the inner nuclear membrane (INM), the nuclear pore complexes, and
lamin, a ﬁlamentous network composed of the A- and B-type lamins.
Lamins are type-V intermediate ﬁlament proteins that associate with
the nuclearmembrane through integral membrane proteins [1]. Molec-
ular communication between the two compartments is performedclear membrane; ONM, Outer
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l rights reserved.exclusively by the nuclear pore complexes. The existence of a continu-
ous network that links the plasmamembrane to the NE and that poten-
tially translates physiological and/or mechanical stimuli into nuclear
reorganization is accepted. In this current view, cytoskeletal and nuclear
structural proteins are no longer regarded as largely passive architec-
tural elements but are currently recognized as also mediating dynamic
regulatory processes, such as macromolecular trafﬁcking through nu-
clear pores, gene expression, and signaling [2]. Therefore, it is not sur-
prising that a growing number of plasma membrane and cytoskeletal
molecules have been found in the nucleus performing structural and/
or regulatory roles; including, EGF receptor and actin [3] reviewed in
[4–6].
Dystroglycan, best known as a central component of theDystrophin-
associated protein complex in muscle, is an important cell adhesion re-
ceptor that links the intracellular skeleton and the extracellular matrix
[7]. Dystroglycan is encoded by a single gene (DAG1) and cleaved
post-translationally into two proteins, resulting in an extracellular
glycoprotein, α-dystroglycan, and a transmembrane glycoprotein,
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other at the cell membrane [8–10]. In addition to the crucial structur-
al role of β-dystroglycan at the plasma membrane, it has recently
been shown that it also functions as a dynamic signal transducingmole-
cule. β-dystroglycan is subject to adhesion-dependent tyrosine phos-
phorylation by Src family kinases [11–13], acts as a scaffold for the
Extracellular signal-related kinase-Mitogen-activated protein (ERK-MAP)
kinase cascade [14], interacts with ezrin to mediate cytoskeleton remod-
eling and to induce peripheral ﬁlopodia and microvilli [15,16], and has
also been implicated in survival signaling through Akt [17,18]. Further-
more, β-dystroglycan in concert with integrins is involved in the dynam-
ics and assembly of cellular adhesions in myoblasts, thereby modulating
myoblast anchorage, motility, and migration [19] reviewed in [20].
To date, all known cellular functions of β-dystroglycan relate to its
localization at the plasma membrane and its interaction with cyto-
skeletal and/or cytoplasmic proteins. Therefore, it was unexpected
to ﬁnd β-dystroglycan in the nucleus of different cell lines [21,22].
This implies the existence of a nuclear targeting mechanism that di-
rects it to the nucleus instead of to the plasma membrane. In this re-
gard, we [23] and others [24] have identiﬁed a functional nuclear
localization signal in the cytoplasmic domain of β-dystroglycan that
mediates the nuclear import of β-dystroglycan through a convention-
al importin α/importin β-dependent pathway [23]. However, the bi-
ological signiﬁcance of β-dystroglycan nuclear localization is largely
unknown. The nucleus of eukaryotic cells is a highly dynamic organ-
elle organized into a large number of specialized domains that per-
form speciﬁc functions, including replication, transcription, RNA
processing, and ribosome biogenesis. Although membrane bound-
aries are absent, nuclear domains can be identiﬁed by distinctive pro-
teins that are used as markers for each compartment. Thus, in this
intricately compartmentalized environment, deﬁnition of the subnu-
clear localization of β-dystroglycan is an essential step to infer and
to further characterize its nuclear function.
In this study, we analyze the association of β-dystroglycan with
protein markers of different nuclear compartments in C2C12 myo-
blasts using immunoﬂuorescence, immunoprecipitation and pull-
down assays, and study the nuclear distribution of β-dystroglycan
at ultra-structural level by electron microscopy analysis. Further-
more, by knock-down of β-dystroglycan expression we reveal that
β-dystroglycan is involved in global nuclear organization function.
2. Materials and methods
2.1. Cell culture
C2C12 cells were grown in Dulbecco's modiﬁed Eagle's Medium
(DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
(v/v) fetal bovine serum, 50 U/ml penicillin, 50 μg/ml streptomycin,
and1 mMsodiumpyruvate at 37 °C in a humidiﬁed 5%CO2 atmosphere.
2.2. Antibodies
Rabbit polyclonal antibodies purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) were utilized as follows: anti-hnRNP C1/C2
(H105; 1:1000 for immunoblotting [WB] and 1:30 for Immunoﬂuores-
cence [IF]); anti-lamin A/C (H-110; 1:4000 for WB and 1:25 for IF);
anti-emerin (FL-254; 1:500 for WB and 1:25 for IF); anti-actin (H196;
1:500 for WB); anti-lamin B1 (H90; 1:1000 for WB and 1:25 for IF);
anti-Nopp140 (H-80; 1:500 for WB and 1:25 for IF); anti-p80-coilin
(H-300; 1:50 for WB and 1:25 for IF); anti-active RNA Polymerase II
(H-224; 1:250 for WB and 1:25 for IF); anti-SC35 (H-55; 1:250 for WB
and 1:40 for IF); anti-Tpr (H-300; 1:500 for WB and 1:40 for IF);
anti-Nup62 (H-122; 1:500 for WB and 1:40 for IF); anti-Sp1 (PEP 2;
1:1500 for WB), and Sp3 (D20X; 1:1500 for WB and 1:30 for IF).
Mouse monoclonal anti-γ-tubulin (1:200 for IF) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Anti-β-dystroglycan antibodiesacquired from Santa Cruz Biotechnology were used as follows: goat
polyclonal antibody (C-20; 1:250 for WB and 1:20 for IF) and mouse
monoclonal antibody (7D11; 1:250 for WB and 1:20 for IF). Finally,
the rabbit polyclonal anti-β-dystroglycan antibody JAF [25] was used
for immunoelectron microscopy at 1:10 dilution.
2.3. Immunoﬂuorescence and confocal microscopy analysis
Cells were ﬁxed with 4% paraformaldehyde for 10 min and
permeabilized by exposure to 0.2% Triton X-100-PBS for 10 min.
For double staining, cells were incubated overnight at 4 °C with pri-
mary anti-β-dystroglycan antibody. The following day, cells were
washed with PBS and incubated for 1 h at room temperature with
secondary Alexa Fluor 594 chicken anti-goat IgG (1:25, Invitrogen)
and processed for double labeling by incubation overnight at 4 °C
with the appropriate antibody. The next day, cells were incubated
with secondary FITC-conjugated goat anti-rabbit IgG (1:25; Zymed
Laboratories, Inc., San Francisco, CA, USA) for 1 h at room tempera-
ture. Nuclei were counterstained with DAPI (0.2 μg/μl, Sigma-
Aldrich) for 20 min at room temperature, washed with PBS, and
mounted on microscope slides with VectaShield (Vector Laboratories,
Inc., Burlingame, CA, USA). For BrdU labeling, cells grown overnight
on coverslips were incubated with BrdU (BD Pharmingen, San Diego,
CA, USA) for 2 h at 37 °C, ﬁxed, permeabilized, and immunostained
with FITC-conjugated BrdU antibody (1:25, BD Pharmingen) for 2 h.
Next, cells were incubated overnight at 4 °C with anti-β-dystroglycan
antibody, washed with PBS, and incubated for 1 h at room temperature
with secondary Alexa Fluor 594 chicken anti-goat IgG (1:25). Finally,
cells were counterstainedwith DAPI andmounted onmicroscope slides
with VectaShield. For nuclear soluble protein removal, C2C12myoblasts
were incubated for 30 min at 4 °C with Triton-CSK extraction buffer
[10 mM Pipes pH 6.8, 100 mM NaCl, 30 mM sucrose, 3 mM MgCl2,
1 mM EGTA, 0.5% (v/v) Triton X-100, 650 mM (NH4)2SO4] and
supplementedwith 1× complete protease inhibitormixture (RocheAp-
plied Science, Indianapolis, IN, USA). Then, cells were processed for im-
munostaining with appropriate primary antibodies, or stained with
DAPI for 20 min at room temperature to visualize DNA. Finally, cells
were mounted on microscope slides with VectaShield and examined
on a confocal laser scanning microscope (TCP-SP5, Leica, Heidelberg,
Germany) employing a Plan Neo Fluor 63x (NA=1.4) oil-immersion
objective.
2.4. Immunoelectron microscopy
Electron microscopy analysis on C2C12 myoblasts was carried out
as previously reported [26] using the anti-β-dystroglycan antibody
JAF (diluted 1:10 in PBS-0.05% Tween-20) or anti-lamin A/C antibody
(diluted 1:5 in PBS-0.05% Tween-20) and secondary antibodies
coupled with colloidal gold particles with a 20-nm diameter (dilution
1:40 in PBS-0.05% Tween-20) (Ted Pella, Inc., Redding, CA, USA).
Preparations were examined in a transmission electron microscope
(JEOL 2000EX, Japan).
2.5. Cell fractionation
Cell lysates were obtained as previously described [27]. To obtain
nuclear extracts, cells were washed twice with 2 ml of ice-cold PBS
and collected by centrifugation at 6000 rpm for 15 min at 4 °C. The
cell pellet was resuspended in TM buffer [10 mM Tris–HCl pH 8.0,
2 mM MgCl2, 0.5 mM PMSF] supplemented with complete 1× and
phosphatase inhibitors [2 mM Na3VO4, 10 mM Na2MoO4, and
25 mM NaF] and incubated for 10 min on ice. Then, 2% Triton
X-100-PBS was added and the homogenate was incubated for
10 min on ice and transferred to a glass Dounce homogenizer,
stroked 30 times with B pestle, and centrifuged at 6000 rpm for
15 min at 4 °C. The nuclear pellet was resuspended in 1 ml of buffer I
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Tris–HCl pH 8.0, 1 mM DTT, 0.5 mM PMSF, 0.5% (v/v) NP40], and 1 ml
of buffer II [2 M Sucrose, 2 mM Mg(COO)2, 0.1 mM EDTA, 10 mM
Tris–HCl pH 8.0, 1 mM DTT, 0.5 mM PMSF] and further puriﬁed by su-
crose gradient centrifugation at 16,000 rpm for 1 h at 4 °C. Nuclei
were recovered with lysis buffer [50 mM Tris–HCl pH 8.0, 150 mM
NaCl, 1 mM PMSF, 1% (v/v) Triton X-100], supplementedwith protease
inhibitor cocktail and phosphatase inhibitors, mixed by vortex for
30 min at 4 °C, sonicated at 4 microns for 2 min, and pre-cleared at
13,000 rpm for 2 min at 4 °C. The supernatant was saved as nuclear
extract for immunoblotting analysis. For nuclear soluble protein re-
moval, puriﬁed nuclei, obtained as described above, was incubated
with Triton-CSK extraction buffer supplemented with 1× complete
protease inhibitor mixture (Roche Applied Science, Indianapolis,
IN, USA) for 30 min at 4 °C, followed by centrifugation at 10,000 g
for 10 min at 4 °C. Soluble proteins were collected, while insoluble
proteins were recovered with lysis buffer supplemented with prote-
ase inhibitor cocktail and phosphatase inhibitors, sonicated at 4 mi-
crons for 2 min, and precleared at 13000 rpm for 2 min at 4 °C. The
supernatant was saved as insoluble extract for immunoblotting
analysis.2.6. Immunoprecipitation assays
Recombinant protein G-agarose beads (8 μl per condition)
(Invitrogen) were equilibrated in 500 μl of lysis buffer [50 mM
Tris–HCl pH 8.0, 150 mM NaCl, 1 mM PMSF, 1% v/v Triton X-100]
and shaken gently for 4 h at 4 °C. Nuclear extracts (1 mg) were
pre-cleared with equilibrated beads for 2 h at 4 °C; next, beads
were removed by centrifugation at 10,000 rpm for 5 min and
pre-cleared extracts were incubated overnight at 4 °C with the ap-
propriate immunoprecipitating antibody. Parallel incubations with
an irrelevant IgG antibody were performed. Thereafter, 8 μl of equil-
ibrated protein G-agarose beads blocked with 4% BSA were added
and incubated overnight at 4 °C. The immune complexes were col-
lected by centrifugation at 10,000 rpm for 5 min, washed three
times for 10 min with 500 μl of wash buffer [50 mM Tris–HCl pH
8.0, 500 mM NaCl, 1 mM EDTA pH 8.0, 1% (v/v) Triton X-100, and
0.5 mM PMSF], and eluted by boiling in 10 μl of milli-Q H2O and
10 μl of SDS sample buffer [50 mM Tris–HCl pH 6.8, 2% (w/v) SDS,
10% (v/v) glycerol, 0.1% (v/v) 2-mercaptoethanol, 0.001% (w/v)
bromophenol blue]. Immunoprecipitated proteins were analyzed
by western blotting.2.7. Western blotting
Protein extracts were electrophoresed on 10% SDS-polyacrylamide
gels and transferred onto nitrocellulose membranes (Hybond-Nþ,
Amersham Pharmacia, GE Healthcare, Buckinghamshire, UK). Mem-
branes were blocked in TBST [100 mM Tris–HCl pH 8.0, 150 mM NaCl,
0.5% (v/v) Tween-20] with low-fat dried milk and then incubated over-
night at 4 °C with the appropriate primary antibody. Speciﬁc proteins
were visualized using the enhanced chemiluminescence (ECL™) West-
ern blotting detection system (Amersham Pharmacia, GE Healthcare)
according to the manufacturer's instructions.2.8. GST binding assays
Glutathione S-transferase (GST) pull-down assays were performed
as previously described [27]. To express and purify GST and GST-β-
dystroglycan, BL21 DE3 bacteria were transformed with pGex-4T1
(Amersham Biosciences, Co., Piscataway. NJ, USA) and pGFP-β-Dg [28]
vectors, respectively.2.9. Cell transfection
C2C12 myoblasts were transfected with the following vectors:
pRNAT-H1.1/Neo vector expressing an interfering RNA (RNAi)
speciﬁc for dystroglycan (CGCAAAGGATCGATCTGTTG), or for an ir-
relevant RNAi (CCCTTATAGAGAGTGGTAGC) and co-expressing the
reporter protein GFP for identiﬁcation of transfected cells (GenScript
Co., Piscataway, NJ, USA). GFP-β-DG vector was generated herein by
PCR ampliﬁcation of human β-DG cDNA from C2C12 cells utilizing
M-MLV reverse transcriptase coupled with high-ﬁdelity polymerase
Pfu turbo (Stratagene) and the following primers; Foward-CTCAGAT
CTATGTCTATCGTGGTGGAATGGACC and Reverse-AGAATTCGAGGGG
GAACATACGGAGG, containing Bgl II and EcoRI restriction sites. The
PCR product was digested with BglI and EcoRI and then cloned into
the pEGFPN1 vector (BD Biosciences, Franklin Lakes, NJ, USA). For in-
direct immunoﬂuorescence assays, 2 μg plasmid DNA in 100 μl
free-serum DMEM medium was mixed with 4 μl lipofectamine
2000 (Invitrogen) and incubated for 30 min at room temperature.
Next, the transfection mixture was mixed with 2 ml fresh medium
(37 °C) prior to being added to C2C12 cells grown on coverslips at
75% conﬂuence. Cells were incubated for 48 h prior to being ana-
lyzed by immunoﬂuorescence and confocal microscopy. For western
blotting experiments, cells seeded on 60-mmwells were transfected
with 4 μg plasmid DNA and 8 μl lipofectamine 2000, as described
above. After 72 h, cells were harvested, nuclear extracts fractionated
and analyzed by western blotting. When indicated, stable transfec-
tion was performed by incubating transfected cells in DMEM con-
taining 800 μg/ml G418 for 30 days. For proteins turnover assays,
cells stably transfected were incubated with 10 μg/ml cycloheximide
(diluted in DMSO) or with DMSO alone in free serumDMEMmedium
for different time intervals. Total extracts were obtained and pro-
cessed for immunoblotting with the appropriate primary antibodies.
2.10. Quantitative reverse transcription PCR (RT-qPCR)
Total RNA from C2C12 cells, stably transfectedwith vectors express-
ing an RNAi speciﬁc for dystroglycan or an irrelevant RNAi, was isolated
with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse tran-
scribed with random hexanucleotides and the M-MLV reverse tran-
scriptase (Invitrogen, Carlsbad, CA, USA), according to manufacturer's
instructions. RT-qPCR reactions were carried out using the commercial
kit ABSOLUTE qPCR SYBR Green Mix (Abgene), and messenger RNA
(mRNA) expression of lamin B1 and emerin was quantiﬁed by the
2ΔΔct method normalized to GAPDH. Primer sequences were as follow:
lamin B1, forward 5′-CTTGAGAATGCCAGACTCTC-3′ and reverse 5′-AA
ACACGCTCTAGACTCTTT-3′; emerin, forward 5′CTTGAGAATGCCAGA
CTCTC-3′ and reverse 5′-GCTCTTGGACATGCCCACAG-3′; GAPDH, for-
ward 5′ CTTGGGCTACACTGAGGACC-3′ and reverse 5′-CTGTTGCTGTA
GCCGTATTC-3′.
2.11. Statistical analysis
Statistical analysis was performed by Student t test using GraphPad
Prism 5.
3. Results
3.1. β-dystroglycan associates with proteins of the nuclear envelope and
nuclear bodies
Subcellular distribution of β-dystroglycan was examined in
C2C12myoblasts by indirect immunoﬂuorescence and confocalmicros-
copy analysis using two different anti-β-dystroglycan antibodies: a goat
polyclonal antibody raised against a peptidemapping at the C-terminus
of β-dystroglycan (C20) and a mouse monoclonal antibody raised
against the C-terminus of β-dystroglycan (7D11). Fig. 1 shows that
Fig. 1. Subcellular distribution of endogenous and GFP-tagged β-dystroglycan in C2C12 myoblasts. (A) Cells cultured on glass cover slips were stained with each of the indicated
anti-β-dystroglycan antibodies (green), and counterstained with phalloidin (red) for visualization of actin network. Samples were imaged using a confocal microscope with a typ-
ical single optical Z-section shown. Bar=25 μm. (B) C2C12 cells cultured on glass cover slips were transiently transfected to express GFP or GFP-β-DG: Cells were ﬁxed 48 h
post-transfection and stained with DAPI to enable the nuclei to be visualized. Cells were imaged by confocal microscopy, with typical single optical Z-sections shown. Scale bars
represent 25 μm.
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dominantly localized to the cytoplasm and plasmamembrane, staining
some potential adhesion-like structures, but notably also to the nuclear
periphery and within the nucleus. To corroborate nuclear localiza-
tion of β-dystroglycan, C2C12 myoblast were transiently transfected
with vector expressing GFP fused to β-dystroglycan (GFP-β-DG), or
GFP alone (control), and transfected cells were imaged by confocal
microscopy. GFP-β-DG was found to be localized throughout the
cell body, including cytoplasm, NE, and nucleoplasm (Fig. 1B), In an
attempt to infer the nuclear function of β-dystroglycan, we as-
certained whether nuclear β-dystroglycan exhibits any speciﬁc
co-localization with previously identiﬁed functional nuclear com-
partments, speciﬁcally the NE, nuclear speckles, Cajal bodies, nucle-
oli, DNA replication sites, and transcription factories. To this end,
C2C12 myoblasts were subjected to double-labeling indirect immu-
noﬂuorescence using both an anti-β-dystroglycan antibody (C20)
and antibodies against each of the different nuclear markers chosen,
and cells were further analyzed by confocal microscopy to show
magniﬁed images of the nucleus. Fig. 2 depicts that immunolabeling
for the three NE proteins analyzed (emerin and lamins A/C and B1)
strongly decorated the nuclear periphery with no signal at the cyto-
plasm, also showing a homogeneous dotted pattern in the nucleoplasm.
Nopp140 immunostaining generated prominent intensively stained
foci, which allowed for distinction of nucleoli, which were positioned
at mid-nucleus, while the anti-p80-coilin antibody strongly labeled
less prominent nucleoplasmic bodies that correspond to Cajal bodies.
Furthermore, splicing speckles were visualized as discrete small foci
with an anti-SC35 antibody, while transcription factories, identiﬁed by
immunolabeling of the active form of RNApolymerase II, were observed
as aggregates localized throughout the nucleus. Finally, BrdU-labeled
nascent DNAwas visualized throughout the nucleus with the exception
of nucleoli, displaying some more intensively stained patches, which
must correspond to more active DNA replication sites. With respect to
β-dystroglycan immunostaining, this generated a punctuate pattern in
the cytoplasm and rim-like labeling at the nucleus, also exhibiting
prominent nuclear bodies in the majority of the cells. Overlaid images
revealed that immunostaining of nuclear β-dystroglycan colocalized
to a certain extent with that of lamin A/C, lamin B1, and emerin at the
nuclear periphery, and with Nopp140-stained nucleoli, SC35-labeled
splicing speckles, and p80-coilin-stained Cajal bodies in the nucleo-
plasm.However,β-dystroglycan exhibited no co-localizationwith tran-
scription factories and DNA replication sites. To validate nuclearenvelope distribution ofβ-dystroglycan, its co-localizationwith NE pro-
teinswas analyzedwith an alternativeβ-dystroglycan antibody (7D11),
Immunostaining of β-dystroglycan was found to be localized in the NE
region overlapping with either lamin A/C, lamin B1 or emerin labeling,
as well as in the nucleoplasm, showing a punctuated pattern (Fig. S1).
Immunoﬂuorescence results imply, therefore, that β-dystroglycan
might interact with different nuclear protein markers. To test this hy-
pothesis, C2C12 nuclear extracts were immunoprecipitated with the
anti-β-dystroglycan antibody C20, and the protein complexeswere sep-
arated by gel electrophoresis. Interaction between β-dystroglycan and
the nuclear compartmentmarkerswas then assessed by immunobloting
employing speciﬁc antibodies (Fig. 3). In C2C12 nuclear lysates, the
anti-β-dystroglycan antibody revealed two immunoreactive bands,
situated between the 50 and 36 kDa markers (Fig. 3A, bottom panel,
Inp lane). It has been observed that phosphorylation of β-dystroglycan
causes an upward mobility shift of the protein [12,14]; thus, the immu-
noreactive band migrating above the expected molecular weight of
β-dystroglycan (43 kDa)might correspond to a phosphorylated variant.
Moreover, higher molecular mass species of β-dystroglycan have been
detected in other studies [29–31]. In all cases, and like us, the authors
were using highly speciﬁc monoclonal antibodies that detect only
β-dystroglycan. We can only assume, therefore, that the slower migrat-
ing forms of β-dystroglycan harbor additional modiﬁcations, however
the nature of those modiﬁcations remains elusive. Immunoreactive
bands corresponding to lamin A/C (65- and 74 kDa), lamin B1
(67 kDa), emerin (34 kDa), p80-coilin (80 kDa), Nopp140 (140 kDa),
and β-dystroglycan itself (43 kDa) were recovered in the anti-β-
dystroglycan immunoprecipitated fraction; however, no bands corre-
sponding to SC35 (35 kDa) or to RNA polymerase II (240 kDa) were
contained in this immunoprecipitate (Fig. 3A). In agreement with this,
reciprocal experiments revealed the presence of β-dystroglycan in im-
munoprecipitates obtained with antibodies against lamin A/C, lamin
B1, emerin, actin, p80-coilin, and Nopp140 but not in those correspond-
ing to SC35 and RNA polymerase II antibodies (Fig. 3B). The second
slower-migrating band of β-dystroglycan (~50 kDa) was present
in some of the nuclear protein immunoprecipitates; nevertheless,
further investigation is required to deﬁne its nature. None of the ana-
lyzed proteins was immunoprecipitated with an unrelated IgG0 anti-
body, conﬁrming assay reliability. To corroborate the association of
β-dystroglycanwith nuclear protein markers, immunoprecipitation as-
says were carried out with an alternative anti-β-dystroglycan antibody
(7D11). Fig. 3C shows that immunoreactive bands corresponding to
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immunoprecipitated with 7D11 but not in that obtained with an irrele-
vant antibody (IgG0). Interaction of β-dystroglycan with its binding
partner actin (43 kDa) [32] was analyzed as positive control, whereas
that with Sp1 (100 kDa) and Sp3 (100 kDa) were utilized as negative
controls [21] (Fig. 3D).
Nuclear pores are embedded in the nuclear envelope, traversing
both the inner and the outer nuclear membranes and the perinuclear
space. Because β-dystroglycan interacts with the three different inner
nuclear membranes proteins analyzed, we hypothesised as to wheth-
er nuclear pore proteins were also associated with β-dystroglycan
and hence examined proteins from two different regions of the pore
structure. We found that both a nuclear pore inner nuclear basket
protein (Tpr, 270 kDa) and a nuclear pore central channel protein
(Nup62, 62 kDa) were absent in β-dystroglycan immunoprecipitates,
and consistently, immunoprecipitates obtained with antibodies
against Tpr and Nup62 failed to precipitate β-dystroglycan (Fig. 3A
and B).
To additionally document the interaction ofβ-dystroglycanwith nu-
clear protein markers, Glutathione-Sepharose transferase (GST) pull-
down assays were carried out, using GST-tagged full-length β-
dystroglycan and C2C12 nuclear extracts. GST or GST-β-dystroglycan
previously immobilized on glutathione-Sepharose beads, were incubat-
edwith nuclear extracts, and the GST-bound endogenous proteinswere
eluted and analyzed by western blotting with speciﬁc antibodies. Eval-
uation of the known interaction between β-dystroglycan and actin
served as positive control. Immunoreactive bands corresponding to
lamin A/C, lamin B1, emerin, Nopp140, p80-coilin, and actin were
recovered as bound to GST-β-dystroglycan but not to GST alone
(Fig. 3E). No detectable binding to GST-β-dystroglycan was observed
for Sp3 (negative control).
3.2. β-dystroglycan is a nucleoskeletal protein that resides in the nuclear
envelope and nucleoli
To analyze the distribution of β-dystroglycan at the ultrastructural
level, immunoelectron microscopy (IEM) analysis was performed on
C2C12myoblasts, utilizing a rabbit polyclonal anti-β-dystroglycan anti-
body termed JAF [25] (Fig. 4A). Upper panels show speciﬁc aggregates
of gold particles in the plasma membrane and the cytoplasm (inset 1,
arrows). Middle panels depict speciﬁc distribution of gold particles in-
side the nucleus, indicating the presence of β-dystroglycan in this or-
ganelle. Magniﬁed images show localization of β-dystroglycan in the
nucleoplasm (inset 1, arrows) and the NE, speciﬁcally in the inner nu-
clearmembrane (INM) (inset 2, arrowhead). Bottompanels display dis-
tribution of β-dystroglycan in the nucleolus (Nu) (inset 1, arrow).
Control immunogold analysis with a anti-lamin A/C antibody (NE pro-
tein) showed the presence of this protein in the INM (Fig. 4B, insets 1
and 2, arrows), conﬁrming the reliability of this analysis. Hence, IEM
data are consistent with the idea that β-dystroglycan resides in the nu-
cleus and is associated with the NE and nucleoli.
To ascertain whether β-dystroglycan behaves as a nucleoskeletal
protein, nucleoskeleton extracts and in situ preparations were ob-
tained by incubating C2C12 cells with extraction buffer (Triton-CSK
buffer), to remove soluble nuclear proteins prior to analysis by immu-
noﬂuorescence and western blotting. To verify the authenticity of the
nucleoskeleton preparations, the distribution of lamin B1, a recog-
nized nucleoskeletal protein, and Sp3, a nuclear soluble protein, wasFig. 2. Co-localization of β-dystroglycan with different nuclear compartments. C2C12 cells se
each of the indicated nuclear proteins (green). Cells were counterstained with DAPI (blue) fo
carried out to show optical sections at nuclear level. Immunolabeling of NE proteins emeri
lamin B1, displayed also a homogeneous dotted pattern in the nucleoplasm. Nopp140 a
while discrete foci that correspond to splicing speckles were visualized with an anti-SC35
replication sites were visualized throughout the nucleus. β-dystroglycan immunostaining w
bodies. Overlaid images showed that β-dystroglycan co-localized with lamin A/C, lamin B1,
splicing speckles in the nucleoplasm (arrows) but not with transcription factories and DNAexamined, as positive and negative controls respectively. Confocal
images shown in Fig. 4C illustrate that most of the nuclear staining
of β-dystroglycan was resistant to this treatment (left panels). As
expected, the majority of lamin B1 immunolabeling remained after
extraction with Triton-CSK buffer (central panels), while Sp3 staining
disappeared upon treatment (right panels). Consistently, western
blotting analysis of cells treated with extraction buffer revealed that
bands corresponding to β-dystroglycan and lamin B1 were recovered
in the precipitated fraction that corresponds to the nucleoskeleton,
while that of Sp3 was mainly present in the supernatant (Fig. 4D).
Overall, these results support the idea that β-dystroglycan is a com-
ponent of the nucleoskeleton.
3.3. β-dystroglycan depletion disrupts the distribution and expression of
nuclear envelope and nuclear bodies proteins
To ascertain whether β-dystroglycan is involved in global nuclear
organization, we analyzed how β-dystroglycan depletion inﬂuences
the morphology of major nuclear compartments by employing a
small interfering RNA (RNAi) to target dystroglycan (DG RNAi). The
RNAi were co-expressed with GFP from the same vector to identify
unequivocally individual RNAi-treated cells. As negative control,
RNAi that is predicted not to block the translation of any speciﬁc
gene was utilized (control RNAi). Effectiveness of RNAi treatment in
reducing β-dystroglycan expression was evaluated by indirect immu-
noﬂuorescence and western blot assays. Global immunolabeling of
β-dystroglycan was drastically reduced in GFP-expressing cells that
co-express DG-speciﬁc RNAi, compared with control RNAi-treated
cells (Fig. 5A). Consistent with this, intensity of the β-dystroglycan
immunoreactive band (~43 kDa) was markedly decreased in both
total and nuclear lysates of C2C12 myoblasts transiently transfected
with vector expressing DG RNAi but not in those expressing the con-
trol RNAi (Fig. 5B). Interestingly, Fig. 5C demonstrates that ablation of
β-dystroglycan expression resulted in a drastic reduction in im-
munolabeling of both lamin B1 and emerin, which are normally dis-
tributed in the nuclear periphery and nucleoplasmic foci (see GFP-
positive cells expressing control RNAi). In β-dystroglycan-depleted
cells, the residual signal corresponding to lamin B1 was scarcely local-
ized to the NE, also exhibiting diffuse staining in the nucleoplasm and
outside the nucleus, where discrete aggregates were noticed. The
remaining emerin labeling found in β-dystroglycan-deﬁcient cells
was mainly redistributed from the NE to the cytoplasm, where dis-
crete patches were noticed. In contrast, analysis of lamin A/C, the third
NE protein analyzed, revealed only a slight immunostaining decrease
in DG RNAi-treated cells, compared with control cells. With respect to
immunoﬂuorescence analysis of nuclear bodies, Nopp140-labeled nu-
cleoli and p80-colin-stained Cajal bodies appeared to be smaller in
size and less intensively stained in β-dystroglycan-depleted cells,
whereas SC35-labeled nuclear speckles exhibited a minimal reduction
in immunolabeling intensity compared with cells expressing the irrele-
vant RNAi.
The reduction in immunolabeling observed in β-dystroglycan-
depleted cells for the majority of nuclear markers analyzed suggests
an effect of β-dystroglycan deﬁciency on their protein levels. To evalu-
ate this idea, nuclear extracts from C2C12 myoblasts stably transfected
with either dystroglycan RNAi or control RNAi were analyzed by west-
ern blotting with antibodies speciﬁc to each nuclear protein. Quantita-
tive analysis of immunoblots employing Sp3 as loading controleded on glass coverslips were ﬁxed and double-stained for β-dystroglycan (red) and for
r nuclei visualization prior to being analyzed by confocal microscopy. Z-sectioning was
n, lamin A/C and lamin B1 decorated the nuclear periphery and with the exception of
nd anti-p80-coilin antibodies labeled the nucleoli and the Cajal bodies respectively,
antibody, RNA polymerase II-containing transcription factories and BrdU-labeled DNA
as distributed to the nuclear periphery and nucleoplasm, decorating prominent nuclear
and emerin at the NE (arrows) and to a certain extent with nucleoli, Cajal bodies, and
replication sites. Scale bar, 5 μm.
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Fig. 3. β-Dystroglycan associates with NE and nuclear bodies protein markers. (A) C2C12 nuclear extracts were immunoprecipitated with the goat polyclonal anti-β-dystroglycan
antibody C20, and eluted proteins separated by SDS-PAGE were subjected to western blotting employing speciﬁc antibodies to nuclear proteins. β-dystroglycan immunoprecipitate
(IP lane) contained lamin A/C, lamin B1, emerin, p80-coilin, Nopp140, and β-dystroglycan itself, but not SC35, active RNA polymerase II, Nup62, or Tpr. None of these proteins were
detected in control IgG immunoprecipitates (IgG0 lane). (B) C2C12 nuclear extracts were subjected to immunoprecipitation with antibodies against different nuclear protein
markers. β-dystroglycan (~43 kDa) was recovered in IgG immunoprecipitates from lamin A/C, lamin B1, emerin, p80-coilin, and Nopp140 but not in those from SC35, RNA poly-
merase II, Nup62, and Tpr (IP lane). None of the speciﬁc bands were observed in immunoprecipitates obtained with irrelevant IgG (IgG0 lane). (C) Nuclear extracts were alterna-
tively immunoprecipitated with the mouse monoclonal anti-β-dystroglycan antibody 7D11. Western blotting analysis showed the presence of lamin A/C, lamin B1, emerin, and
Nopp140 in the fraction immunoprecipitated with 7D11 (IP lane) but not in fractions obtained with an irrelevant antibody (IgG0). (D) Western blot analysis of β-dystroglycan im-
munoprecipitates showing actin (positive control), but not Sp1 and Sp3 (negative controls). (E) GST and GST-β-dystroglycan (GST-β-DG) proteins expressed in a bacterial system
were immobilized on glutathione-Sepharose beads and subsequently incubated with C2C12 nuclear extracts to perform pull-down assays. Eluted proteins were analyzed by immu-
noblotting utilizing appropriate antibodies. Nuclear proteins lamin A/C, lamin B1, emerin, Nopp140, and actin (positive control) were pulled-down together with
GST-β-dystroglycan, but not with GST alone. Neither GST nor GST-β-dystroglycan were associated with Sp3 (negative control). In all gels, IP, Immunoprecipitation; WB, Western
blotting. Input, nuclear extracts prior to be subjected to immunoprecipitation or pull-down assays. Arrows denote the migration of the expected proteins.
704 I.A. Martínez-Vieyra et al. / Biochimica et Biophysica Acta 1833 (2013) 698–711revealed that β-dystroglycan depletion indeed caused a substantial de-
crease (~50%) in lamin B1, emerin, Nopp140, and p80-coilin protein
levels, but not in those corresponding to lamin A/C and SCS35Fig. 4. Analysis of β-dystroglycan nuclear organization. (A) Cytoplasmic and nuclear distrib
blasts were immunostained with anti-β-dystroglycan (JAF) or anti-lamin A/C antibodies and
and methods). The top panels show distribution of β-dystroglycan in the plasma membra
β-dystroglycan in the nucleus (N) (left, panel), associated with the nucleoplasm (inset 1,
show prominent immunorecognition of the anti-β-dystroglycan antibody in the nucleolu
and 2, arrows). Scale bar is indicated in each panel. (C) Effect of Triton-high salt extraction on
by incubating C2C12 cell with Triton-CSK extraction buffer for 20 min, to remove nucle
(nucleoskeleton protein) or Sp3 (nuclear soluble protein), and counterstained with DAPI
at constant settings, and Z-sectioning was carried out to show optical sections at nu
immunolabeling. Scale, 5 μm. (D) Equal amounts of nucleoskeleton extracts, obtained by Tr
munoblotting analysis. Proteins were visualized using speciﬁc antibodies against β-dystrog
β-dystroglycan and laminB1 were recovered in the nucleoskeleton fraction (P), while Sp3 w(Fig. 6A). To ascertain whether β-dystroglycan deﬁciency affects ex-
pression of nuclear proteins at transcriptional level, we analyzed
messenger RNA (mRNA) expression of lamin B1 and emerin byution of β-dystroglycan was determined by immunoelectron microscopy. C2C12 myo-
revealed with secondary antibody conjugated with 20-nm gold particles (see Materials
ne (M) and the cytoplasm (Cy) (inset 1, arrows). The middle panels show labeling of
arrow) and the inner nuclear membrane (INM) (inset 2, arrowhead). Bottom panels
s (Nu) (inset 1, arrow). (B) Lamin A/C immunogold localization in the INM (insets 1
β-dystroglycan nuclear distribution. In situ nucleoskeleton preparations were obtained
ar soluble proteins. Treated cells were immunostained for β-dystroglycan, lamin B1
to visualize DNA. Immunoﬂuorescence images were analyzed by confocal microscopy
clear level. Detergent extraction preserved the majority of β-dystroglycan nuclear
iton-high salt extraction, as described in Materials and methods, were subjected to im-
lycan, lamin B1 (positive control), and Sp3 (negative control). The expected bands for
as present as a higher proportion in the supernatant fraction (S). N, nuclear extracts.
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mRNA expression of lamin B1 and emerin was similar between control
and β-dystroglycan-depleted cells. Since β-dystroglycan-depleted cells
exhibitedmislocalization of lamin B1 and emerin, we hypothesized that
deﬁciency of β-dystroglycan might alter the stability of these NE pro-
teins. To test this idea, control and β-dystroglycan-depleted cells wereFig. 5. β-Dystroglycan depletion alters immunostaining and distribution of nuclear envelope
vector expressing either the control or the DG RNAi. (A) After 72 h, cells were subjected to β
GFP co-expression (green). An example of DG RNAi-treated cells displaying reduced β-dystr
25 μm. (B) Western blotting analysis showing depleted levels of β-dystroglycan in total and
loading controls for total and nuclear lysates, respectively. (C) Localization of nuclear marke
blasts transfected with control RNAi or DG RNAi vectors were immunostained with antib
(blue), prior to being analyzed by confocal microscopy. Z-sectioning was carried out to sho
In control RNAi-treated myoblasts, the immunostaining pattern of NE proteins lamin A/C,
β-dystroglycan-depleted cells exhibited a severe decrease in the immunolabeling of lamin
teins redistributed from the NE to the cytoplasm (arrows). Immunolabeling of nuclear boditreated with cycloheximide to inhibit protein synthesis, and the stabil-
ity of emerin and lamin B1 was monitored for a period of 3 hours. Con-
sistent with our hypothesis, turnover of lamin B1 and emerin was
accelerated in β-dystroglycan-depleted cells, compared with control
cells (Fig. 6C and D). Overall, these data strongly indicate that
β-dystroglycan is critical for targeting of emerin and lamin B1 at NE asand nuclear body protein markers. C2C12 myoblasts were transiently transfected with
-dystroglycan immunoﬂuorescence staining (red). Transfected cells were identiﬁed by
oglycan immunolabeling is shown, compared with control RNAi-treated cells. Scale bar,
nuclear lysates of cells transfected with DG RNAi. GAPDH and actin were employed as
rs by indirect immunoﬂuorescence in control and β-dystroglycan-deﬁcient cells. Myo-
odies against nuclear markers (red) and counterstained with DAPI to visualize nuclei
w optical slices at nuclear level. GFP-positive cells identiﬁed transfected cells (green).
lamin B1, and emerin displayed a continuous rim at the nuclear periphery, whereas
B1 and emerin, but not of lamin A/C. The remaining signal corresponding to these pro-
es is also slightly affected when β-dystroglycan expression is deﬁcient. Scale bar, 5 μm.
Fig. 6. β-Dystroglycan-deﬁcient cells exhibit decreased expression of protein markers from nuclear envelope and nuclear bodies. (A) Nuclear extracts from C2C12 myoblasts stably
transfected with vector expressing either control RNAi or DG RNAi were analyzed by western blotting. Blots were stripped and reprobed successively with each nuclear protein
antibody, using Sp3 to normalize protein measurements; relative protein levels obtained in control RNAi-transfected cells were set at 1. Results are the mean±standard deviation
(SD) of three independent experiments. Asterisks denote signiﬁcant differences between control RNAi- and DG RNAi-treated cells (p≤0.05). Protein levels corresponding to lamin
B1, emerin, Nopp140, and p80-coilin displayed a ~50% decrease in β-dystroglycan-depleted cells, whereas those of lamin A/C and SC35 remained unaltered, compared with control
cells. (B) Messenger RNA expression of lamin B1 and emerin was examined by quantitative reverse transcription PCR in control RNAi- or DG RNAi-treated C2C12 cells, as described
in Materials and methods. Relative mRNA levels obtained in control cells were set at 1. Results are the mean±SD of three independent experiments. The mRNA expression of lamin
B1 and emerin was unaltered in β-dystroglycan-depleted cells. (C) To arrest protein synthesis, C2C12 cells stably transfected with vector expressing either control RNAi or DG RNAi
were treated with cyycloheximide (CHX) or DMSO (vehicle), and protein levels of lamin B1 and emerin were monitored by western blotting in total protein extracts for 3 hours. (D)
Quantitative analysis using GAPDH as loading control is shown. Protein expression at time 0 h was set at 1 for comparison. Results are the mean±SD of three independent exper-
iments. β-dystroglycan-depleted cells exhibited altered stability of lamin B1 and emerin.
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mislocalization of emerin and lamin B1, due to β-dystroglycan deple-
tion, appears to alter their half-life.
3.4. β-dystroglycan is involved in nuclear envelope-associated functions
To determine the functional relevance of β-dystroglycan associa-
tion with NE proteins, we downregulated β-dystroglycan using
RNAi. We tested the hypothesis that β-dystroglycan downregulation
with concomitant mislocalization and decrease in lamin B1 and
emerin levels, compromises NE functions. We therefore analyzed NE
processes in which lamin B1 and emerin have crucial roles, such as nu-
clear morphology [33–36], and centrosome linkage to the outer nuclear
membrane [37]. To this end, C2C12 myoblasts were transfected with
vector expressing control or dystroglycan RNAi and maintained for
30 days in G418-containing medium to isolate RNAi-expressing cells
speciﬁcally. Antibodies against γ-tubulin and DAPI staining were usedFig. 7. Deﬁciency of β-dystroglycan disrupts nuclear envelope-associated functions. (A
β-dystroglycan-depleted myoblasts. Cells stably transfected with vector expressing either
anti-γ-tubulin antibody (red) to localize centrosomes. (A) An example of centrosome positi
cated by white lines, were measured in overlaid images using Leica Application Suite, Advan
from triplicate experiments each utilizing 200 cells; mean±SD. (B) Representative images
shows data from triplicate experiments as above. (C) Examples of nuclear morphology
graph on the right shows quantiﬁcation of the number of perturbed nuclei in DG RNAi-treat
mal if spheroid or ellipsoid, and abnormal if blebbed, lobulated, or if they were at least twic
control RNAi- and DG RNAi-treated cells (p≤0.05).to determine centrosome position relative to the nucleus in DG
RNAi-treated cells. In control RNAi-treated cells, centrosomes were lo-
cated juxtaposed or within 0.75 μm of the nucleus; in contrast,
β-dystroglycan-depleted cells displayed an average centrosome-
nucleus distance of 1.80 μm, a value that is similar to the increase in cen-
trosome distance reported for emerin-null human diploid ﬁbroblasts,
comparedwith normalﬁbroblasts [37] (Fig. 7A). Hence, our data demon-
strate that β-dystroglycan depletion in C2C12 myoblasts interferes with
the linkage of centrosomes to the outer nuclear membrane, which has
been shown to depend, at least in part, on a microtubule-emerin path-
way [37]. Remarkably, we also observed a very high percentage (17%)
of β-dystroglycan-deﬁcient cells containing multiple centrosomes,
(ranging from three to six), compared with only 2% of control cells
(Fig. 7B). These ﬁndings suggest that emerin and/or or β-dystroglycan
itself are involved in centrosome duplication. To analyze the effects of
β-dystroglycan knockdown on nuclear morphology, we examined
DAPI-stained cells after β-dystroglycan downregulation. We found aand B) Nuclear–centrosome distance and centrosome number are increased in
control RNAi or DG RNAi were stained with DAPI to image nuclei (blue) and with
on in control and DG RNAi-treated cells is shown. Nuclear–centrosome distances, indi-
ced Fluorescence Lite imaging processing software. The graph on the right shows data
showing centrosome number found in control and DG RNAi-treated cells. The graph
in DAPI-stained nuclei isolated from control and β-dystroglycan-depleted cells. The
ed cells compared with control RNAi-treated cells (n=300). Nuclei were scored as nor-
e as large or small as those in controls. Asterisks denote signiﬁcant differences between
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RNAi treatment, either; markedly irregular, with blebbing or that was
at least two-fold larger or smaller in relation to control cell nuclei
(Fig. 7C).
4. Discussion
In this study, we report the association of β-dystroglycan with
proteins distinctive of different nuclear domains. We also reveal
that such interactions are functionally relevant, because depletion
of β-dystroglycan resulted in decreased expression and disrupted lo-
calization of NE proteins lamin B1 and emerin, as well as in disrupted
organization of nucleoli, splicing speckles, and Cajal bodies. Further-
more electron microscopy analysis provides compelling evidence
that β-dystroglycan resides in the INM, nucleoplasm, and nucleoli.
Overall, our data demonstrate that β-dystroglycan is a structural
component of the NE required for proper targeting of emerin and
lamin B1 to the NE, which ultimately might confer stability upon
these proteins. The following evidence supports this model:
1) β-dystroglycan is targeted to the INM likely via its transmem-
brane domain, 2) localization of lamin B1 and emerin to the NE is de-
pendent upon the presence of β-dystroglycan as evidenced by
displacement of lamin B1 and emerin from the NE in β-dystroglycan-
deﬁcient cells, and 3) β-dystroglycan-depleted cells displayed acceler-
ate turnover of emerin and lamin B1 proteins. It was previously
shown that laminsA/C, and B1 all interactwith emerin in vivo; however,
lamin A, but not lamin B1, appears to be necessary for anchorage of
emerin to the NE in HeLa and SW13 cells [38]. Thus, it was intriguing
to ﬁnd that β-dystroglycan-depleted cells with normal lamin A/C orga-
nization at the NE exhibit disrupted emerin localization and expression.
It has been observed in vivo that A- and B-type lamins preferentially
form homopolymers and that heterotypic interaction of lamins occurs
between juxtaposed A- and B-type lamin homopolymers [39]. Further-
more, it was reported in amphibian oocytes that different lamin
proteins form distinctive individual ﬁlaments with characteristic orga-
nization. B-type lamins form thin, highly organized layers that are close-
ly associated with membranes, whereas lamin A forms thick bundles
and layers on top that add to the mechanical rigidity of the NE [40].
Therefore, a molecular model consistent with our results is that NE lo-
calization of emerin in C2C12 myoblasts is determined by the lamin
B1 network instead of that of lamin A/C. We postulate that
β-dystroglycan interacts with emerin and lamin B1 to modulate their
targeting to the NE; then, emerin might associate with lamin B1 ﬁla-
ments to acquire stabilization at the NE. Supporting this idea, emerin
was co-immunoprecipitated from C2C12 lysates in a complex con-
taining both lamin A/C and lamin B1 [41]. Further interaction experi-
ments in vivo testing binary or multimeric interactions between
lamins A/C and B1 with β-dystroglycan and emerin, are necessary to
characterize the β-dystroglycan-containing NE complex in detail.
As shown here β-dystroglycan association with emerin and
lamin B1 is functionally relevant because a primary deﬁciency in
β-dystroglycan with concomitant elimination of emerin and lamin
B1 from the NE disturbed two cellular characteristics that are deter-
mined by the NE, nuclearmorphology and centrosome attachment to
the NE. It is well-established that lamin proteins [33–36] and emerin
[42] are critical for nuclear shape; therefore, it is plausible to propose
that β-dystroglycan contributes to nuclear shape by interacting in a
complex with emerin and lamin B1 at the NE. Furthermore it was
recently reported that emerin is essential for centrosome linkage to
the ONM via its interaction with microtubules [37]. Therefore, the
increased fraction of β-dystroglycan-depleted cells with detached cen-
trosomes indicates that β-dystroglycan deﬁciency might compromise
the microtubule-emerin pathway, which controls centrosome tethering
to the ONM. Unexpectedly, a high fraction of cells with decreased
β-dystroglycan expression exhibited multiple centrosomes. Since there
is no previous report linking the centrosome duplication cycle with NEor with β-dystroglycan itself, the precise role of β-dystroglycan in this
event remains to be established. Dystroglycan depletion has been
shown previously to affect the progression of the cell cycle [43,44] but
centrosome positioning of duplication was not addressed in these
studies. Nonetheless, because defects in centrosome number can lead
to loss of cell polarity, defective cell division, and abnormal chromo-
some segregation [45], all events typical of cancerous cells, and as
down-regulation of β-dystroglycan has been observed in a large num-
ber of epithelial-derived tumors [46,47], it is tempting to speculate
that centrosome over-duplication associated with β-dystroglycan deﬁ-
ciency could contribute to the tumor phenotype.
It is noteworthy that β-dystroglycan represents, to our knowledge,
the ﬁrst identiﬁed protein that belongs to the two principal cellular
complexes involved in the development of muscular dystrophies. On
the one hand, β-dystroglycan is a transmembrane component of the
Dystrophin-associated protein complex, which is composed of dystro-
phin, dystroglycans, sarcoglycans, syntrophins, dystrobrevins), and
sarcospan [48]. DAPC disruption underlies the molecular pathogenesis
of a variety of muscular dystrophies, revealing that the extracellular
matrix-cytoskeleton linkage is critical for sarcolemma integrity. Pri-
mary mutations in the dystrophin gene cause Duchenne muscular dys-
trophy [49], whereas autosomal recessive limb-girdle muscular
dystrophies result from mutations in the sarcoglycans genes [50].
With the exception of one isolated case [51] genetic defects in DAG1
(encoding dystroglycan) itself have not yet been identiﬁed in human
disease; defects in glycosyltransferases implicated in α-dystroglycan
glycosylation have been shown to cause a subset of muscular dystro-
phies called dystroglycanopathies, reviewed by [52]. On the other
hand, β-dystroglycan also constitutes a novel NE component that
might be involved in NE stability and function, as previously stated.
The critical role of the NE in cell/tissue function has been highlighted
by the identiﬁcation of a variety of human diseases, ranging from can-
cers to certain forms of muscular dystrophies that are linked with mu-
tations in proteins of the nuclear pore, the INM, and the nuclear
lamina [53–56]. Speciﬁcally, mutations in NE proteins emerin and
lamin A/C cause X-linked and autosomal-dominant forms of Emery–
Dreyfuss muscular dystrophy (EDMD), respectively [55,57]. In light of
our data, we consider it important and timely to examine the potential
contribution ofβ-dystroglycan to themolecular etiologies of EDMD; be-
cause, changes in β-dystroglycan expression or function could alter
emerin and/or lamins AC and B1 distribution in architectural or in reg-
ulatory complexes with speciﬁc pathologic consequences.
To deﬁne the relevance of the nuclear localization of β-dystroglycan
further analysis in other study models is warranted. Different trans-
genic mice for β-dystroglycan have been generated in recent years:
mice with conditional deletion of dystroglycan in striated muscle and
central nervous system exhibited mild muscular dystrophy and brain
malformations respectively [58,59], while mouse carrying a deletion
of the entire cytoplasmic domain of β-dystroglycan displayed an atten-
uation of the electroretinogram b-wave in glial cells [60] and mdx
mouse with a Y890F substitution that prevents phosphorylation of
β-dystroglycan at the PPxY motif showed amelioration of the dystro-
phic phenotype [61]. Although none of these studies reported nuclear
alterations, it is note toworth that analyses conducted in the transgenic
mice were focused speciﬁcally at organ and tissue levels. Thus the exis-
tence of a nuclear phenotype cannot be ruled out until further analyses
at cellular level are approached in these animal models.
In addition to the proposed role of β-dystroglycan in NE structure
and function, we demonstrated that β-dystroglycan is also involved
in the organization of nuclear bodies (see previous sections). Al-
though the potential role of β-dystroglycan in speciﬁc functions asso-
ciated with each nuclear compartment remains to be elucidated, the
fact that lamin B1 is involved in nucleoli organization [62], preserving
its functional plasticity [63], opens the possibility that β-dystroglycan
might modulate nucleoli structure and function through its functional
association with lamin B1.
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Our results suggest that β-dystroglycan has a role in modulating
nuclear architecture and NE function in myoblasts via its interaction
with different nuclear structures. These interactions may be regulated
in a dynamic way through the regulated import of β-dystroglycan to
the nucleus [23] and might contribute to either scaffolding or modu-
lation of transcriptionaly active regions of the cell. Dynamic regula-
tion of nuclear import coupled with the cell division cycle or cell
differentiation for example, could give rise to the variable appearance
of nuclear dystroglycan, as seen in other studies [24,64].
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